Clara Andradas
Assessment of Cannabidiol and ∆9-Tetrahydrocannabiol in Mouse Models of Medulloblastoma and Ependymoma
Andradas, Clara; Byrne, Jacob; Kuchibhotla, Mani; Ancliffe, Mathew; Jones, Anya C; Carline, Brooke; Hii, Hilary; Truong, Alexandra; Storer, Lisa C D; Ritzmann, Timothy A; Grundy, Richard G; Gottardo, Nicholas G; Endersby, Raelene
Authors
Jacob Byrne
Mani Kuchibhotla
Mathew Ancliffe
Anya C Jones
Brooke Carline
Hilary Hii
Alexandra Truong
Lisa C D Storer
Dr Timothy Ritzmann Timothy.Ritzmann1@nottingham.ac.uk
CLINICAL ASSOCIATE PROFESSOR
Professor RICHARD GRUNDY richard.grundy@nottingham.ac.uk
PROFESSOR OF PAEDIATRIC NEURO-ONCOLOGY
Nicholas G Gottardo
Raelene Endersby
Abstract
Children with medulloblastoma and ependymoma are treated with a multidisciplinary approach that incorporates surgery, radiotherapy, and chemotherapy; however, overall survival rates for patients with high-risk disease remain unsatisfactory. Data indicate that plant-derived cannabinoids are effective against adult glioblastoma; however, preclinical evidence supporting their use in pediatric brain cancers is lacking. Here we investigated the potential role for ∆9- tetrahydrocannabinol (THC) and cannabidiol (CBD) in medulloblastoma and ependymoma. Dose- dependent cytotoxicity of medulloblastoma and ependymoma cells was induced by THC and CBD in vitro, and a synergistic reduction in viability was observed when both drugs were combined. Mechanistically, cannabinoids induced cell cycle arrest, in part by the production of reactive oxygen species, autophagy, and apoptosis; however, this did not translate to increased survival in orthotopic transplant models despite being well tolerated. We also tested the combination of cannabinoids with the medulloblastoma drug cyclophosphamide, and despite some in vitro synergism, no survival advantage was observed in vivo. Consequently, clinical benefit from the use of cannabinoids in the treatment of high-grade medulloblastoma and ependymoma is expected to be limited. This study emphasizes the importance of preclinical models in validating therapeutic agent efficacy prior to clinical trials, ensuring that enrolled patients are afforded the most promising therapies available.
Citation
Andradas, C., Byrne, J., Kuchibhotla, M., Ancliffe, M., Jones, A. C., Carline, B., Hii, H., Truong, A., Storer, L. C. D., Ritzmann, T. A., Grundy, R. G., Gottardo, N. G., & Endersby, R. (2021). Assessment of Cannabidiol and ∆9-Tetrahydrocannabiol in Mouse Models of Medulloblastoma and Ependymoma. Cancers, 13, Article 330. https://doi.org/10.3390/cancers13020330
Journal Article Type | Article |
---|---|
Acceptance Date | Jan 15, 2021 |
Online Publication Date | Jan 18, 2021 |
Publication Date | Jan 2, 2021 |
Deposit Date | Jan 18, 2021 |
Publicly Available Date | Feb 12, 2021 |
Journal | Cancers |
Publisher | MDPI |
Peer Reviewed | Peer Reviewed |
Volume | 13 |
Article Number | 330 |
DOI | https://doi.org/10.3390/cancers13020330 |
Public URL | https://nottingham-repository.worktribe.com/output/5242552 |
Files
Cancers-13-00330
(7 Mb)
PDF
Publisher Licence URL
https://creativecommons.org/licenses/by/4.0/
You might also like
Downloadable Citations
About Repository@Nottingham
Administrator e-mail: discovery-access-systems@nottingham.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2025
Advanced Search